Intuitive Surgical shares (NASDAQ:ISRG) have been testing support around $400, with the price hovering close to 52 week lows, as the stock struggles to find a footing this year. It is a completely different picture when you zoom out, yet there are fears amongst markets that previously unshakeable moats could be exposed by AI.
ISRG shares are listed on the Nasdaq rather than the ASX, yet the US-based medical device company’s business model offers an interesting case study for Australian investors interested in healthcare megatrends and long-term compounding. Down 27% year to date but up more than 100% over the past six years, Intuitive Surgical operates a razor-and-blade model in robotic surgery that generates predictable recurring revenue regardless of broader market conditions.
Intuitive Surgical has installed 11,395 robotic surgery systems globally and controls approximately 80% of the robotic surgery market. The company generates 86% of its revenue from recurring sources, primarily consumable instruments and accessories used in each procedure, plus service contracts on installed systems.
The core product, the da Vinci surgical system, is a multi-million-dollar capital purchase for hospitals. Once installed, each procedure requires single-use instruments, which Intuitive supplies. The more systems in the field, the more predictable the consumables revenue becomes.
Top Australian Brokers
- Pepperstone - Top Australian broker - Read our review
- eToro - Invest in ASX and international shares - Read our review
This is not a traditional capital goods manufacturer dependent on quarterly equipment sales. It is a healthcare infrastructure play where the installed base creates a compounding revenue stream that persists through economic cycles.
Why does it matter?
The durability thesis rests on the recurring revenue model. Each installed system generates ongoing consumables revenue for years after the initial sale. As the installed base grows, the revenue floor rises.
Robotic surgery adoption is still in its early stages globally. Procedures performed using da Vinci systems continue to grow as surgeons become trained, hospital systems expand access, and clinical evidence supports robotic-assisted techniques across more procedure types.
For Australian investors, Intuitive Surgical represents exposure to an aging global population, rising healthcare spending, and the shift toward minimally invasive surgery. The valuation has compressed in 2026, with the share price down 27% year to date, yet this does not change the underlying consumables model, it creates a lower entry point for those willing to take a longer term view.
ASX listed companies in the sector that have a similar ‘razor-and-blade’ model include Nanosonics (ASX: NAN), ResMed (ASX: RMD), and Pro Medicus (ASX: PME).
Threats incoming?
Intuitive Surgical operates in a sector where regulatory approval, clinical training, and hospital purchasing cycles move slowly. This creates high barriers to entry and makes the installed base sticky. Once a hospital invests in a da Vinci system and trains its surgical staff, switching costs are high.
The company benefits from network effects. As more procedures are performed, more clinical data is generated, which supports further adoption. Surgeons trained on da Vinci systems tend to prefer them. Hospitals compete to offer robotic surgery as a service differentiator.
Recurring revenue from consumables and service contracts provides cash flow stability. This allows the company to invest in research and development, expand into new procedure types, and buy back shares during market downturns.
The perceived threat in recent times has come with the innovation taking place in AI. There was a big drawdown earlier in the year that has persisted amongst software names, with the ‘moats’ that previously appeared unshakeable with high costs potentially changing.
Key signals to monitor include system installation growth, procedures per system, geographic expansion, and new procedure approvals. If the installed base continues to grow and utilisation per system increases, the recurring revenue stream strengthens.
